Pharmaco-epidemiological description of the population of the Marche Region (central Italy) treated with the antipsychotic drug olanzapine

Annali dell'Istituto Superiore di Sanita

Volumn 49, Issue 1, 2013, Pages 42-49

  Mignini, Fiorenzo ^a   Sabbatini, Maurizio ^b   Pascucci, Chiara ^a   Petrelli, Fabio ^a   Grappasonni, Iolanda ^a   Vanacore, Nicola ^c  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Defined daily dose index; Incidence index; Prevalence index; Psychiatric drug

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AGE; AGED; ARTICLE; FEMALE; HUMAN; ITALY; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PSYCHOSIS; STATISTICS; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84875439010     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN-13-01-08     Document Type: Article

References (35)

1. Lee PE, Gill SS, Freedman M, Bronskill SE, Hilmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behaviour and psychological symptoms of dementia: systematic review. Br Med J 2004;329:75-9. DOI: 10.1136/bmj.38125. 465579.55
2. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000;321:1371-6. DOI: 10.1136/bmj.321.7273.1371
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64. DOI: 10.1001/archpsyc.60.6.553
4. Kapur S, Remington G. Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects. Br Med J 2000;321:1360-1.
5. Lambert M, Naber D. Current issues in schizophrenia: overview of patients acceptability, functioning capacity and quality of life. CNS Drugs 2004;18:5-17.
6. The Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43:25S-40S.
7. Treatment of schizophrenia. The Expert Consensus Guideline Series. J Clin Psychiatry 1999;60:3-80.
8. Ananth J, Parameswaran S, Gunatilake S. Side effect of atypical antipsychotic drugs. Curr Pharm Des 2004;10:2219-29.
9. Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008;100:70-85. DOI: 10.1016/j. schres.2007.11.026
10. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 2005;21:1-10.
11. Herrmann R, Lanctot KL. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? Drug Saf 2006;29:833-43.
12. Committee on Safety of Medicine. Atypical antipsychotic drugs and stroke. London: Medical and Healthcare products Regulatory Agency; 2004. Available from: www.mhra.gov. uk/Safetyinformation/Safetywarningsalertsandrecalls/ Safetywarningsandmessagesformedicines/CON1004298.
13. Italia. Ministero della Salute. Chiarimenti riguardanti la prescrivibilità dei farmaci antipsicotici atipici da parte delle UVA. Farmacovigilanza News 2004;7:8-4.
14. Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioural disturbances. Silver-Springer (MD) USA: FDA; 2005.
15. Hamann J, Ruppert A, Auby P, Pugner K, Kissling W. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol 2003;18:237-42.
16. Apiquian R, Fresan A, De La Fuente-Sandoval C, Nicolini H, Ulloa RE. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription pattern. BMC Psychiatry 2004;4:12. DOI: 10.1186/1471-244X-4-12
17. Trifirò G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Pharmacol 2005;61:47-53. DOI: 10.1007/s00228-004-0868-3
18. Hollingworth SA, Siskind DJ, Nissen LM, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia 2002-2007. Aust NZ J Psychiatry 2010;44:372-7. DOI: 10.3109/00048670903489890
19. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Luis Vàzquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode non affective psychosis. J Clin Psychiatry 2006;67:1511-21.
20. Cuesta MJ, Jalon EG, Campos MS, Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009;194:439-45. DOI: 10.1192/bjp. bp. 108.055137
21. Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry 2009;70:1501-13. DOI: 10.4088/JCP.08m04446yel
22. Smith RC, Lindenmayer JP, Hu Q, Kelly E, Viviano TF, Cornwell J, Vaidhyanathaswamy S, Marcovina S, Davis JM. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with longterm antipsychotic treatment: A randomized five month study. Schizophr Res 2010;120:204-9. DOI: 10.1016/j. schres.2010.04.001
23. Percudani M, Barbui C, Fortino I, Tansella M, Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 2005;25:468-70.
24. Sink KM, Holden KF, Yafffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608. DOI: 10.1001/jama.293.5.596
25. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in anti psychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010;35:1997-2004. DOI: 10.1038/npp. 2010.78
26. Martins PJ, Haas M, Obici S. Central nervous system delivery of antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 2010;59:2418-25. DOI: 10.2337/db10-0449
27. Barbui C, Danese A, Guaiana G, Mapelli L, Miele L, Monzani E, Percudani M. Study group. Prescribing second-generation antipsychotic and the evolving standard of care in Italy. Pharmacopsychiatry 2002;35:239-43. DOI: 10.1055/s-2002-36394
28. Chiabrando G, Bianchi S, Poluzzi E, Montanaro N, Scanavacca P. Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. Eur J Clin Pharmacol 2010;66:661-9. DOI: 10.1007/s00228-010-0828-z
29. Agenzia Italiana del Farmaco (AIFA) website, 2005. Available from: www.agenziafarmaco.gov. it/it/content/iltrattamento-farmacologico-dei-disturbi- psicotici-pazientiaffetti-da-demenza.
30. Franchi C, Tettamanti M, Merengoni A, Bonometti F, Pasina L, Cortesi L, Fortino I, Bortolotti A, Merlino L, Lucca U, Riva E, Nobili A. Changes in trends of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicine Agency. Results from the EPIFARM-Elderly project. Eur Neuropsychopharmacol 2012;22:569-77. DOI: 10.1016/j.euroneuro.2011.12.009
31. Mirandola M, Andretta M, Corbari L, Sorio A, Nosè M, Barbui C. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf 2006;15:412-20. DOI: 10.1002/pds.1162
32. Alacqua M, Trifirò G, Arcoraci V, Germanò E, Magazù A, Calarese T, Di Vita G, Gagliano C, Spina E. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a pediatric setting. Pharm World Sci 2008;30:44-50.
33. WHO Collaborating Centre for Drug Statistics and Methodology. Guidelines for ATC classification and DDD assignment. Oslo: WHO; 2001.
34. Trifirò G, Sini G, Sturkenboom MC, Vanacore N, Mazzaglia G, Caputi AP, Cricelli C, Brignoli O, Aguglia E, Biggio G, Samani F. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia. Int Clin Psychopharmacol 2012;25:22-8. DOI: 10.1097/YIC.0b013e3283334f08
35. Steinberg M, Corcoran C, Tschanz JT, Huber C, Welsh-Bohmer K, Norton MC, Zandi P, Breitner JC, Steffens DC, Lyketsos CG. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2006;21:824-30. DOI: 10.1002/gps.1567